Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Allografting

Imatinib mesylate versus allogeneic BMT for patients with chronic myeloid leukemia in first chronic phase

Bone Marrow Transplantation volume 42, pages 597–600 (2008)Cite this article

Abstract

Imatinib mesylate (IM) is now first-line treatment for CML. To study the results of treatment with IM after IFN failure/intolerance versus allogeneic BMT (allo-BMT), we retrospectively analyzed 264 patients treated for CML in first chronic phase in three different institutions. Over a 6-year period (2001–2006), 174 patients received IM after failure of or intolerance to IFN. During the same period of time, 90 patients received an allo-BMT from an HLA-matched sibling (n=83) or an unrelated donor (n=7). The IM group was older (41 versus 33 years, P<0.001). Five-year EFS was 62% among patients receiving IM and 52% among patients undergoing allo-BMT (P=0.0002). OS at 5 years was 93% for IM-treated patients and 59% for patients undergoing allo-BMT (P<0.0001). Allo-BMT cannot be considered as first-line treatment for CML patients in first chronic phase.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038–1042.

    Article  CAS  PubMed  Google Scholar 

  2. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031–1037.

    Article  CAS  PubMed  Google Scholar 

  3. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994–1004.

    Article  CAS  PubMed  Google Scholar 

  4. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408–2417.

    Article  CAS  PubMed  Google Scholar 

  5. Roy L, Guilhot J, Krahnke T, Guerci-Bresler A, Druker BJ, Larson RA et al. Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials. Blood 2006; 108: 1478–1484.

    Article  CAS  PubMed  Google Scholar 

  6. Gratwohl A, Brand R, Apperley J, Crawley C, Ruutu T, Corradini P et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006; 91: 513–521.

    PubMed  Google Scholar 

  7. Giralt SA, Arora M, Goldman JM, Lee SJ, Maziarz RT, McCarthy PL et al. Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia. Br J Haematol 2007; 137: 461–467.

    Article  CAS  PubMed  Google Scholar 

  8. Deininger M, Schleuning M, Greinix H, Sayer HG, Fischer T, Martinez J et al. The effect of prior exposure to imatinib on transplant-related mortality. Haematologica 2006; 91: 452–459.

    CAS  PubMed  Google Scholar 

  9. Oehler VG, Gooley T, Snyder DS, Johnston L, Lin A, Cummings CC et al. The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. Blood 2007; 109: 1782–1789.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Hehlmann R, Berger U, Pfirrmann M, Heimpel H, Hochhaus A, Hasford J et al. Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood 2007; 109: 4686–4692.

    Article  CAS  PubMed  Google Scholar 

  11. Hochhaus A, Druker B, Sawyers C, Guilhot F, Schiffer CA, Cortes J et al. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. Blood 2008; 111: 1039–1043.

    Article  CAS  PubMed  Google Scholar 

  12. Passweg JR, Walker I, Sobocinski KA, Klein JP, Horowitz MM, Giralt SA . Validation and extension of the EBMT Risk Score for patients with chronic myeloid leukaemia (CML) receiving allogeneic haematopoietic stem cell transplants. Br J Haematol 2004; 125: 613–620.

    Article  PubMed  Google Scholar 

  13. Weisser M, Ledderose G, Jochem Kolb H . Long-term follow-up of allogeneic HSCT for CML reveals significant improvement in the outcome over the last decade. Ann Hematol 2007; 86: 127–132.

    Article  PubMed  Google Scholar 

  14. Schmitz N, Eapen M, Horowitz MM, Zhang MJ, Klein JP, Rizzo JD et al. Long-term outcome of patients given transplants of mobilized blood or bone marrow: A report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. Blood 2006; 108: 4288–4290.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Sanz GF, Saavedra S, Jimenez C, Senent L, Cervera J, Planelles D et al. Unrelated donor cord blood transplantation in adults with chronic myelogenous leukemia: results in nine patients from a single institution. Bone Marrow Transplant 2001; 27: 693–701.

    Article  CAS  PubMed  Google Scholar 

  16. Kebriaei P, Detry MA, Giralt S, Carrasco-Yalan A, Anagnostopoulos A, Couriel D et al. Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia. Blood 2007; 110: 3456–3462.

    Article  CAS  PubMed  Google Scholar 

  17. Kantarjian H, Talpaz M, O'Brien S, Garcia-Manero G, Verstovsek S, Giles F et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2004; 103: 2873–2878.

    Article  CAS  PubMed  Google Scholar 

  18. Shah NP . Medical management of CML. Hematol Am Soc Hematol Educ Program 2007; 2007: 371–375.

    Article  Google Scholar 

Download references

Acknowledgements

We thank Heliz Neves, Ingrid Mito, Gustavo Magalhaes and Claudia de Souza.

Author information

Authors and Affiliations

  1. Hematology and Stem Cell Transplantation Service, Hospital das Clinicas da Universidade Federal de Minas Gerais, Belo Horizonte, Brazil

    H Bittencourt, S Magalhães, A V Macedo & N Clementino

  2. Hematology and Stem Cell Transplantation Service, Hospital de Clinicas da Universidade Federal do Paraná, Curitiba, Brazil

    V Funke, D Setubal, J Ruiz, A P Azambuja & R Pasquini

  3. Hematology and Stem Cell Transplantation Service, Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil

    L Fogliatto, A Paz & L Silla

Authors
  1. H Bittencourt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. V Funke
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L Fogliatto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S Magalhães
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D Setubal
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A Paz
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A V Macedo
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J Ruiz
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. A P Azambuja
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. L Silla
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. N Clementino
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. R Pasquini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H Bittencourt.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bittencourt, H., Funke, V., Fogliatto, L. et al. Imatinib mesylate versus allogeneic BMT for patients with chronic myeloid leukemia in first chronic phase. Bone Marrow Transplant 42, 597–600 (2008). https://doi.org/10.1038/bmt.2008.218

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2008.218

Keywords

This article is cited by

Search

Advanced search

Quick links